NorthlineHealth
Join
← FormularyTracking · Category 2

GH Fragment · Lipolytic Peptide

AOD-9604

Adipose / metabolic

Status
On watchlist — not yet prescribable
Get notified on reclassification

Mechanism

AOD-9604 is a modified fragment of human growth hormone (hGH176–191) with the addition of a tyrosine at the N-terminus. It retains the lipolytic activity of GH without binding to the GH receptor or affecting IGF-1 levels, avoiding the mitogenic risks associated with full-length GH. It stimulates fat breakdown and inhibits lipogenesis.

Indications

→Targeted fat metabolism without GH receptor activation
→Adipose tissue reduction
→Metabolic syndrome adjunct
→Cartilage repair (separate mechanism, early research)

Regulatory status

AOD-9604 received FDA GRAS status in 2014 as a food ingredient but has no drug approval. It is on the 503A Category 2 list for injectable compounding. Northline does not prescribe and monitors regulatory status.

References

01Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. 2001.
02FDA 503A Category 2 — ineligible for compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.